# A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.

> **NCT07185243** · NA · RECRUITING · sponsor: **Hangzhou Converd Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** recombinant human IL-21-expressing oncolytic vaccinia virus injection

## Key facts

- **NCT ID:** NCT07185243
- **Lead sponsor:** Hangzhou Converd Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-23
- **Primary completion:** 2027-06
- **Final completion:** 2028-06
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185243, "A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07185243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*